Print Friendly and PDF

Psilocybin May Help Ease Depression in Cancer Patients

In small trial, half had early remission of depressive symptoms after psilocybin-assisted therapy

December 18, 2023 9:00 am

By Diana Swift

Psilocybin-assisted therapy in a group setting was safe and appeared effective in patients with cancer and depression, according to a small, phase II, open‐label trial.

After one dose of psilocybin among 30 patients, depression severity scores dropped … Read more

Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer

December 15, 2023 9:00 am

By Edward Winstead

For people being treated for cancer, participating in virtual mind–body fitness classes may have important benefits, such as reducing the risk of being hospitalized for treatment-related problems, according to results from a clinical trial.

In the trial, … Read more

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

December 6, 2023 9:00 am

By James H. Doroshow, M.D.

More than 8 years ago, NCI launched NCI-MATCH, a first-of-its-kind precision medicine cancer clinical trial. NCI-MATCH tested different targeted therapies in people with cancer whose tumors had specific genetic changes. This year, three second-generation precision

… Read more

Ovarian Cancer Detected Early With DNA From Pap Smear in Proof-of-Principle Study

December 6, 2023 9:00 am

By Andrea Anderson

NEW YORK – An Italian team led by investigators at Humanitas University has come up with a test for detecting early-stage high-grade serous ovarian cancer (HGSOC) that relies on DNA sequencing of cervical smear samples collected during … Read more

From diagnosis through survivorship: Mindfulness can help people cope with cancer

Research has shown mindful meditation can reduce stress, relieve pain.

November 29, 2023 9:00 am

Clearity offers psychosocial support to caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with caring for a loved one with an ovarian cancer diagnosis, our team of OC … Read more

PC14586 Targets Previously “Undruggable” p53 in Treatment of Solid Tumors

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.

November 27, 2023 9:00 am

By Kyle Doherty

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity. With the initiation of the phase … Read more

Artificial Intelligence May Predict Ovarian Cancer Therapy Outcomes

November 21, 2023 9:00 am

By Rylan DeStefano

An artificial intelligence model called IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy) shows an 80% accuracy rate in the prediction of therapy outcomes for patients with ovarian cancer. The artificial intelligence model focuses specifically on the volumetric … Read more

Raludotatug Deruxtecan Elicits Early Efficacy and Safety in Platinum-Resistant Ovarian Cancer

November 17, 2023 9:00 am

Clearity’s Perspective: A phase I clinical trial studying the antibody-drug conjugate (ADC) raludotatug deruxtecan (DS-6000a, R-DXd) shows early encouraging activity in heavily pretreated ovarian cancer. The antibody portion of raludotatug deruxtecan targets CDH6 (found in about 65-85% of ovarian cancers) … Read more

Scientists Piece Together DNA Repair Pathway Implicated in Breast, Ovarian, and Prostate Cancers

November 15, 2023 9:00 am

Clearity’s Perspective: Cancer cells that have mutations in BRCA or that are HRD-positive are not able to use the so-called homologous recombination repair pathway to fix mistakes in the cancer cell. These cancer cells become reliant on other repair pathways. … Read more

Claudine Isaacs, MD, on the Limitations of At-Home Genetic Tests for Hereditary Breast/Ovarian Cancers

More than 95% of BRCA1 or BRCA1 pathogenic variants would have been missed by DTC testing, largest such study showed

November 8, 2023 9:00 am

By Mark Fuerst

Direct-to-consumer (DTC) genetic testing has limited use as a screening tool for identifying individuals at risk of hereditary breast or ovarian cancer, especially in those of non-Ashkenazi Jewish descent, researchers reported.

Most current DTC genetic tests evaluate … Read more

T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers

November 7, 2023 9:00 am

RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer

November 5, 2023 9:00 am

Clearity’s Perspective: The combination of avutometinib and defactinib has shown encouraging activity in Low-Grade Serous Ovarian Cancer. Updated results from the RAMP 201 trial suggest that the combination is active regardless of the number of prior therapies patients have received. … Read more

Celebrating Life While Honoring Death: Q&A with our Oncology Chaplain, Michael Eselun

October 20, 2023 9:00 am

Michael Eselun, Clearity’s Oncology Chaplain, sat down with our Director of Education, Danielle Peterson, to discuss what occasions like the Jewish New Year Celebration, Rosh Hashanah, and Día de los Muertos can teach us about the role the contemplation of … Read more

Liquid Biopsy Shows Promise to Distinguish Benign Pelvic Masses from Tumorous Ones

October 11, 2023 9:00 am

A new liquid biopsy test developed by researchers at USC Norris Comprehensive Cancer Center has shown promise to distinguish which pelvic masses are benign and which are tumorous, a development that could aid early diagnosis of high-grade serous ovarian carcinoma … Read more

Phase 3 Trial of TTFields and Paclitaxel Misses OS End Point in Ovarian Cancer

August 28, 2023 9:00 am

The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.

Patients with platinum-resistant ovarian cancer given tumor treating fields

… Read more

Batiraxcept Plus Paclitaxel Misses PFS End Point in Platinum-Resistant Ovarian Cancer

August 3, 2023 9:00 am

The addition of batiraxcept to paclitaxel did not significantly improve progression-free survival compared with paclitaxel alone in a prespecified subset of patients with platinum-resistant ovarian cancer who were not previously exposed to bevacizumab, missing the primary end point of the … Read more

Aerobic exercise may reduce chemotherapy-induced peripheral neuropathy in ovarian cancer

August 2, 2023 9:00 am

Key takeaways:

  • Women assigned a 6-month intervention reported decreased chemotherapy-induced peripheral neuropathy symptoms.
  • Women in the control group reported a slight increase in symptoms.

A 6-month aerobic exercise intervention significantly improved self-reported chemotherapy-induced peripheral neuropathy among women who underwent chemotherapy … Read more

Upifitamab Rilsodotin Fails to Meet ORR End Point in NaPi2b+ Platinum-Resistant Ovarian Cancer

July 27, 2023 9:00 am

The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.

 

The phase 1/2 UPLIFT trial (NCT03319628) … Read more

Avutometinib Plus Defactinib Demonstrates Promising Activity in Recurrent LGSOC

June 6, 2023 7:03 am

Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the … Read more